Coverage and reimbursement for Macrilen™ (macimorelin) 60 mg for oral solution

Coverage and reimbursement for Macrilen™ (macimorelin) 60 mg for oral solution

Coverage and reimbursement for Macrilen™ (macimorelin) 60 mg for oral solution

Coverage for Macrilen™

Complete an electronic form to verify your patient’s benefits (both pharmacy and medical). Once you’ve completed your portion of the form, simply provide your patient’s email address and we’ll send them a patient authorization form to sign.

Complete the Service Request Form

Co-pay Savings Program

Eligible commercially insured patients may pay as little as $0, with an annual cap of $1,000.a Register to enroll your patients in the Macrilen™ Co-pay Savings Program and file claims electronically.

Get started

For more information or assistance, please call a NovoCare® representative at 1-888-668-6444. Available Monday through Friday from 8:00 am to 8:00 pm ET.

All Claims V2

Selected Important Safety Information

Warnings and Precautions

  • QT Prolongation: Macrilen™ causes an increase of about 11 msec in the corrected QT (QTc) interval. QT prolongation can lead to development of torsade de pointes-type ventricular tachycardia with the risk increasing as the degree of prolongation increases. The concomitant use of Macrilen™ with drugs that are known to prolong the QT interval should be avoided

Indication and Limitation of Use

Macrilen™ (macimorelin) 60 mg for oral solution is indicated for the diagnosis of adult growth hormone deficiency (AGHD).

  • The safety and diagnostic performance of Macrilen™ have not been established for subjects with a body mass index (BMI) >40 kg/m2

Important Safety Information cont’d

Warnings and Precautions

  • Potential for False Positive Test Results with Use of Strong CYP3A4 Inducers: Concomitant use of strong CYP3A4 inducers with Macrilen™ can decrease macimorelin plasma levels significantly and thereby lead to a false positive result. Strong CYP3A4 inducers should be discontinued and enough time should be given to allow washout of CYP3A4 inducers prior to test administration
  • Potential for False Negative Test Results in Recent Onset Hypothalamic Disease: Adult growth hormone (GH) deficiency caused by a hypothalamic lesion may not be detected early in the disease process. Macimorelin acts downstream from the hypothalamus and macimorelin stimulated release of stored GH reserves from the anterior pituitary could produce a false negative result early when the lesion involves the hypothalamus. Repeat testing may be warranted in this situation

Adverse Reactions

  • The most common adverse reactions are dysgeusia, dizziness, headache, fatigue, nausea, hunger, diarrhea, upper respiratory tract infection, feeling hot, hyperhidrosis, nasopharyngitis, and sinus bradycardia

Please click here for Prescribing Information